관리자

04/29/2019

IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine

https://www.outsourcing-pharma.com/Article/2019/04/23/IVI-receives-15.7m-to-conduct-Ph-III-trials-of-typhoid-vaccine? Outsourcing-pharma.com,  2019/04/23
04/23/2019

IVI’s 19th International Vaccinology Course – Register Now!

04/18/2019

IVI-led CAPTURA consortium wins Fleming Fund award for work on antimicrobial resistance (AMR) data across Asia

SEOUL, South Korea — An international consortium, led by the International Vaccine Institute (IVI), has received funding from the UK’s Fleming Fund Regional Grants to conduct the Capturing Data on Antimicrobial Resistance (AMR) Patterns and Trends in Use in Regions of Asia (CAPTURA) project. The […]
04/17/2019

IVI receives $15.7 million grant to conduct phase III trials of new Vi-DT typhoid conjugate vaccine manufactured by SK bioscience of Korea

– Grant from the Bill & Melinda Gates Foundation will support additional supply of novel TCV at affordable cost for public sector markets   SEOUL, Korea –The International Vaccine Institute (IVI) announces receipt of a $15.7 million-dollar grant from the Bill & Melinda Gates Foundation […]